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Abstract 
Background: Nef is a multifunctional accessory protein encoded by HIV‑1, HIV‑2 and SIV that plays critical roles in 
viral pathogenesis, contributing to viral replication, assembly, budding, infectivity and immune evasion, through 
engagement of various host cell pathways.
Results: To gain a better understanding of the role of host proteins in the functions of Nef, we carried out tandem 
affinity purification‑mass spectrometry analysis, and identified over 70 HIV‑1 Nef‑interacting proteins, including the 
autophagy‑related 9A (ATG9A) protein. ATG9A is a transmembrane component of the machinery for autophagy, a 
catabolic process in which cytoplasmic components are degraded in lysosomal compartments. Pulldown experi‑
ments demonstrated that ATG9A interacts with Nef from not only HIV‑1 and but also SIV (cpz, smm and mac). 
However, expression of HIV‑1 Nef had no effect on the levels and localization of ATG9A, and on autophagy, in the host 
cells. To investigate a possible role for ATG9A in virus replication, we knocked out ATG9A in HeLa cervical carcinoma 
and Jurkat T cells, and analyzed virus release and infectivity. We observed that ATG9A knockout (KO) had no effect 
on the release of wild‑type (WT) or Nef‑defective HIV‑1 in these cells. However, the infectivity of WT virus produced 
from ATG9A‑KO HeLa and Jurkat cells was reduced by ~ fourfold and eightfold, respectively, relative to virus produced 
from WT cells. This reduction in infectivity was independent of the interaction of Nef with ATG9A, and was not due to 
reduced incorporation of the viral envelope (Env) glycoprotein into the virus. The loss of HIV‑1 infectivity was rescued 
by pseudotyping HIV‑1 virions with the vesicular stomatitis virus G glycoprotein.
Conclusions: These studies indicate that ATG9A promotes HIV‑1 infectivity in an Env‑dependent manner. The inter‑
action of Nef with ATG9A, however, is not required for Nef to enhance HIV‑1 infectivity. We speculate that ATG9A could 
promote infectivity by participating in either the removal of a factor that inhibits infectivity or the incorporation of a 
factor that enhances infectivity of the viral particles. These studies thus identify a novel host cell factor implicated in 
HIV‑1 infectivity, which may be amenable to pharmacologic manipulation for treatment of HIV‑1 infection.
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Background
Viruses need to circumvent the intrinsic defenses of their 
hosts in order to replicate and disseminate. To this end, 
primate lentiviruses such as human immunodeficiency 
viruses (HIV-1, HIV-2) and simian immunodeficiency 
viruses (SIV) have evolved to encode several virulence 
factors that create favorable conditions for viral repli-
cation within their host cells. Prominent among these 
factors is Nef, an accessory protein encoded in all HIV-
1, HIV-2 and SIV genomes that is highly expressed 
early after infection (reviewed in Refs. [1, 2]). Nef is a 
27–35 kDa N-terminally myristoylated protein that asso-
ciates with the cytosolic face of membranes (Fig.  1a). 
Structural studies have shown that Nef comprises sev-
eral folded segments (comprising residues 55–65, 84–148 
and 178–203) flanked by flexible segments [3–6] (Fig. 1a) 
(amino-acid residue numbers correspond to the NL4-3 
variant of HIV-1 Nef). A flexible loop connecting the 
folded 84–148 and 178–203 segments becomes struc-
tured when it binds to one of its targets, the clathrin-
associated adaptor protein complex AP-2 [7].
Nef has been reported to promote multiple aspects of 
the viral life cycle, including replication, assembly, bud-
ding, infectivity and immune evasion, through engage-
ment of various cellular pathways [1, 2]. Among these 
pathways are protein trafficking, intracellular signaling 
and autophagy. In some cases, Nef causes redistribution 
and/or degradation of cellular proteins [8–10], as exem-
plified by the downregulation of the HIV-1 receptor CD4 
[11] and coreceptors CCR5/CXCR4 [12], class I mol-
ecules of the histocompatibility complex (MHC-I) [13] 
and the viral restriction factors SERINC3 and SERINC5 
[14–18], from the surface of infected cells. The mecha-
nisms of Nef-induced CD4 and MHC-I downregulation 
are well understood, involving the formation of tripartite 
complexes of these proteins with Nef and the clathrin 
adaptors AP-2 [7] and AP-1 [6], respectively. Nef is also 
capable of activating various cellular kinases such as 
members of the p21-activated kinase (PAK) [19, 20] and 
Src families [21]. Furthermore, Nef has been reported to 
inhibit autophagy through interactions with components 
of the autophagy machinery such as beclin 1 [22, 23], 
syntaxin 17 and IRGM [24]. However, many aspects of 
Nef function remain insufficiently understood, so there 
is a need to identify additional host cell targets. Several 
methods have been used to identify HIV-1 Nef interac-
tors, including classical yeast two-hybrid screens [25, 
26], a split-ubiquitin-based yeast two-hybrid system [27], 
affinity purification followed by peptide microsequence 
analysis [28] and proteomic analysis using tandem affin-
ity purification (TAP)-mass spectrometry (MS) [29–32]. 
Although a number of Nef-binding proteins were identi-
fied in these studies, many have not been independently 
validated and their potential roles in Nef function and 
HIV pathogenesis remain to be determined.
To undertake a more comprehensive and detailed anal-
ysis of lentiviral Nef interactors, we performed TAP-MS 
using as baits the Nef proteins from one HIV-1 strain 
(NL4-3) and three SIV strains [from chimpanzee (cpz), 
macaque (mac) and sooty mangabey (smm)] expressed 
by stable transfection into HEK-293T cells. After filtering 
the results to remove frequent contaminants, we ended 
up with dozens of proteins that interacted with one or 
more of the Nefs. Among these, we chose for further 
study the transmembrane autophagy protein ATG9A. 
We found that Nef and ATG9A did not alter each other’s 
localization or levels in HeLa cervical carcinoma or Jur-
kat T cells. Moreover, expression of Nef had little or no 
effect on autophagy in these cells. However, while knock-
out (KO) of the ATG9A gene did not affect the release of 
HIV-1 particles, it greatly decreased the infectivity of the 
particles. This effect was independent of the interaction 
Fig. 1 Identification and validation of HIV‑1 and SIV Nef interactors. a Schematic representation of FTS‑tagged Nef constructs used for TAP‑MS. Nef 
is myristoylated (Myr) at the N‑terminus and comprises three folded domains (represented in blue) (residues 55–65, 84–148 and 178–203 in HIV‑1 
Nef; residues 87–97, 116–180 and 212–235 in SIVsmm Nef ) flanked by flexible segments, comprising an N‑terminal flexible anchor (residues 1–54 
in HIV‑1 Nef; residues 1–86 in SIVsmm Nef ) and a C‑terminal flexible loop (residues 149–177 in HIV‑1 Nef; residues 181–211 in SIVsmm Nef ). SIVcpz 
Nef is similar to HIV‑1 Nef and SIVmac to SIVsmm. The FTS tag is composed of one FLAG tag (DYKDDDK) followed by two strep tags (WSHPQFEK). 
b Flowchart of the TAP‑MS protocol conducted to identify Nef‑interacting proteins. Detergent extracts of HEK‑293T cells stably expressing 
FTS‑tagged Nef from the HIV‑1 NL4‑3 strain or from three SIV strains (SIVcpz, SIVmac and SIVsmm) were incubated with Strep‑Tactin beads and 
bound proteins eluted with desthiobiotin. The eluate was further purified by binding to anti‑FLAG M2 beads and elution with FLAG peptide. Eluted 
proteins were identified by MS. Raw data were filtered against the CRAPome database, and interaction maps were generated using BioGRID. c 
Interaction map of HIV‑1 Nef with host proteins identified by TAP‑MS and grouped according to their cellular functions. d Classification of HIV‑1 
Nef interactors according to their cellular compartments. e Validation of TAP‑MS hits by pulldown (PD) and immunoblotting (IB). HeLa cells were 
transfected with plasmids encoding Nef from HIV‑1 or the three SIV strains, as well as myrlysin or lyspersin as specificity controls, all tagged with 
FTS. Cells were cross‑linked, lysed and the FTS‑tagged proteins isolated on Strep‑Tactin beads. The isolated proteins were analyzed by SDS‑PAGE 
and immunoblotting with antibodies to endogenous PAK3, SPTLC2 and ATG9A, as well as antibody to the FLAG epitope. The positions of molecular 
mass markers (in kDa) are indicated on the left. The > 70‑kDa species observed in the lyspersin‑FTS pulldown is likely a non‑specific protein that is 
recognized by the antibody to SPTLC2
(See figure on next page.)
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of ATG9A with Nef, but dependent on the envelope gly-
coprotein (Env) of HIV-1. These findings thus identified 
ATG9A as a novel host cell factor that promotes the pro-
duction of infectious HIV-1 particles in a Nef-independ-
ent but Env-dependent manner.
Results
Identification of host cell proteins that interact with HIV‑1 
and SIV Nef
To identify host cell proteins that interact with Nef, we 
conducted a TAP-MS analysis, following the procedure 
outlined in Fig. 1b. Nef proteins from the HIV-1 NL4-3 
strain and the three SIV strains (cpz GAB1, mac239 
and smm FWR1) were tagged with sequences encod-
ing one FLAG and two strep tags (herein referred to as 
FLAG-Two-Strep or FTS) at the C-terminus (Fig.  1a), 
and expressed by stable transfection in HEK-293T cells. 
Detergent extracts from these cells were subjected to 
sequential affinity purification on Strep-Tactin and anti-
FLAG M2 affinity beads. Affinity-purified proteins were 
identified by liquid chromatography followed by MS 
(Additional file  1: Table  S1). The results were filtered 
against the Contaminant Repository for Affinity Purifica-
tion Mass Spectrometry Data (CRAPome) database [33] 
to remove frequent contaminants in TAP-MS. This pro-
cedure yielded 73 proteins that co-purified with HIV-1 
Nef (Fig.  1c), 17 with SIVcpz Nef, 27 with SIVmac Nef 
and 19 with SIVsmm Nef (Additional file 2: Figure S1A). 
The interactors included proteins that are involved in 
trafficking, autophagy, solute transport, ubiquitina-
tion, ER/Golgi structure, nuclear processes and cellular 
metabolism (Fig. 1c), and that localize to various cellular 
compartments (Fig. 1d). Some interactors were common 
to two or more Nefs. Among these were the subunits 
of the exocyst (i.e., EXOC1-EXOC8) (Fig.  1c and Addi-
tional file  2: Figure  S1A, B), a tethering complex that 
was previously shown to interact with HIV-1 Nef, and to 
promote Nef-mediated enhancement of nanotube forma-
tion [30] and regulation of actin remodeling [34]. Other 
common interactors included components of a complex 
comprising the p21 activated kinase 3 (PAK3), the ARF 
GTPase-activating proteins 1 and 2 (GIT1 and GIT2), 
and the Rac/Cdc42 guanine nucleotide exchange factor 
6 (ARHGEF6) (Fig. 1c and Additional file 2: Figure S1A, 
B). Interaction of HIV-1 or SIV Nef with a similar com-
plex comprising the paralogous PAK2 has been shown to 
activate the kinase activity of PAK2 and to promote Nef 
phosphorylation and viral replication [20, 35–38]. The 
connection of other common interactors (Additional 
file 2: Figure S1B) to HIV-1 replication and/or pathogen-
esis remains to be determined.
To validate selected hits from our screen, we trans-
fected HeLa cells with plasmids encoding FTS-tagged 
Nef from HIV-1 or the three SIV strains, as well as the 
myrlysin or lyspersin subunits of BLOC-1-related com-
plex (BORC) [39] as specificity controls. Cells were cross-
linked with dithiobis succinimidyl propionate (DSP) to 
stabilize interactions, and solubilized FTS-tagged pro-
teins were pulled down with Strep-Tactin beads. Endog-
enous proteins that co-isolated with the FTS-tagged 
proteins were identified by immunoblotting. We chose 
to perform this validation for three interactors that could 
be detected by commercially available antibodies and 
that were of particular interest to us. PAK3 was chosen 
because of its homology to the Nef kinase PAK2 [20, 
35–38]. The serine palmitoyl transferase long chain base 
subunit 2 (SPTLC2) was chosen because it is involved in 
the biosynthesis of sphingolipids, which are important 
contributors to HIV-1 infectivity [40, 41]. Finally, the 
transmembrane autophagy-related protein 9A (ATG9A) 
was chosen because of the reported connections of Nef 
to autophagy [22–24]. Our pulldown-immunoblotting 
experiments revealed that PAK3, SPTLC2 and ATG9A 
indeed co-isolated with all four Nefs (Fig.  1e), even 
though in the original TAP-MS PAK3 only co-purified 
with SIVcpz and SIVmac, SPTLC2 with HIV-1 and SIV-
mac, and ATG9A with HIV-1 (Fig.  1c and Additional 
file 2: Figure S1). PAK3, SPTLC2 and ATG9A were pulled 
down to a much lesser extent with tagged myrlysin and 
lyspersin (Fig. 1e), supporting the specificity of the inter-
actions with the four Nefs. The fact that these proteins 
were not co-isolated with all four Nefs in the TAP-MS 
experiment could be explained by the use of a cross-link-
ing agent in the pulldown experiments and by the higher 
sensitivity of immunoblotting.
Nef does not affect ATG9A localization, ATG9A levels 
and autophagy
Of the hits in our screen, we chose to focus on ATG9A 
because it had not been previously shown to interact 
with Nef, and because of the reported roles of autophagy 
in the HIV-1 replication cycle [42]. In addition, this was 
a protein that was already under study in our laboratory 
for other reasons [43, 44]. ATG9A is a multispanning 
membrane protein with N-terminal and C-terminal tails 
facing the cytosol [45]. Because Nef functions to down-
regulate transmembrane proteins such as CD4, MHC 
class I, CXCR4, CCR5 and SERINC3/5 from the surface 
of host cells [11–18, 46], we examined the effect of tran-
siently expressing HIV-1 Nef-GFP on the localization 
and levels of endogenous ATG9A in HeLa cells. Immu-
nofluorescence microscopy showed that, in the absence 
of Nef, endogenous ATG9A was distributed through-
out the cytoplasm, although with a higher concentra-
tion at the trans-Golgi network (TGN), as detected by 
co-staining for TGN46 (Fig.  2a). This distribution was 
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in line with the reported cycling of ATG9A between the 
TGN and peripheral autophagosomal structures [45, 47]. 
HIV-1 Nef-GFP exhibited a similar localization to the 
TGN and peripheral structures in addition to the plasma 
membrane (Fig.  2a), as previously reported [16, 48–50]. 
The co-localization of ATG9A with Nef was consistent 
with the interaction of these proteins detected by TAP-
MS and Strep-Tactin pulldown (Fig. 1). However, immu-
nofluorescence microscopy showed that expression of 
Nef-GFP did not alter the overall localization and stain-
ing intensity of ATG9A (Fig. 2a). Moreover, immunoblot 
analysis revealed that stable expression of HIV-1 Nef-
GFP in both HeLa and Jurkat cells had no effect on the 
levels of endogenous ATG9A (Fig.  2b). Thus, unlike the 
downregulation of surface CD4, MHC class I, CXCR4, 
CCR5 and SERINC3/5, the intracellular localization and 
levels of ATG9A were unaltered by expression of Nef.
ATG9A participates in the early stages of autophagy, 
presumably by delivering lipids to phagophore assembly 
sites (PAS) [51, 52]. This function of ATG9A promotes 
the conversion of the autophagy protein LC3 (ortholo-
gous to yeast Atg8) from a soluble, cytosolic form (LC3-I) 
to a lipidated, membrane-bound form (LC3-II) [53]. This 
conversion can be monitored by SDS-PAGE and serves 
as an indicator of autophagic activity. Using this assay, 
we found that stable expression of HIV-1 Nef-GFP did 
not significantly alter the ratio of endogenous LC3-I and 
LC3-II to actin in either HeLa or Jurkat cells (Fig. 2c). In 
line with this observation, stable expression of Nef-GFP 
also had no effect on the punctate appearance and stain-
ing intensity of endogenous LC3-II in the cytoplasm of 
either HeLa or Jurkat cells (Additional file 2: Figure S2). 
Similarly, transient expression of Nef-GFP did not alter 
the number of LC3 puncta per cell (unpublished obser-
vations). After fusion of autophagosomes with lysosomes 
to form autolysosomes, LC3-II is degraded by lysosomal 
acid hydrolases [54]. Incubation of cells with chloroquine 
inhibits the hydrolases, resulting in accumulation of LC3-
II in autolysosomes and thus providing a measure of 
“autophagic flux” [55]. Indeed, we found that incubation 
of both HeLa (Fig. 2d) and Jurkat cells (Fig. 2e) with chlo-
roquine resulted in a time-dependent increase in the 
levels of LC3-II, without alteration in the levels of LC3-
I. Stable expression of HIV-1 Nef-GFP in these cells had 
little or no effect on the kinetics and extent of LC3-II 
increase, or on the steady levels of LC3-I, upon chloro-
quine treatment (Fig. 2d, e). Therefore, expression of Nef 
does not affect autophagic flux. Further analyses showed 
that stable expression of Nef-GFP slightly increased the 
levels of beclin-1 but did not alter the levels of other com-
ponents of the autophagy machinery, including ATG7, 
ATG5, ATG12, ATG16, LAMP-1 and SNAP29 in either 
HeLa or Jurkat cells (Additional file 2: Figure S3). The fact 
that there were no differences in autophagic flux, how-
ever, indicated that the increase in beclin-1 levels induced 
by the co-expression of HIV-1 Nef had no impact on the 
process. From these experiments, we concluded that Nef 
does not cause major alterations in autophagy in HeLa 
and Jurkat cells despite its interaction with ATG9A.
The intracellular distribution of Nef is independent 
of ATG9A and autophagy induction
We next addressed the converse possibility that ATG9A 
influenced the intracellular localization of Nef. To this 
end, we used the CRISPR/Cas9 system to inactivate the 
ATG9A gene in both HeLa and Jurkat cells. Immuno-
blot analysis confirmed the absence of ATG9A protein 
in the KO cells (Additional file 2: Figure S4A, C). HIV-1 
Nef-GFP was then stably expressed in these cells and its 
intracellular localization determined by confocal micros-
copy. We observed that ATG9A KO did not affect the 
levels (Additional file 2: Figure S4A, C) and intracellular 
distribution (Additional file  2: Figure  S4B, D) of Nef-
GFP in either HeLa or Jurkat cells. In addition, we tested 
if the distribution of stably expressed Nef-GFP in HeLa 
and Jurkat cells was affected by induction of autophagy 
by treatment with the mTORC1 inhibitor Torin1 or by 
incubation in amino-acid- and serum-free medium. 
We observed that, while these treatments increased the 
number of cytoplasmic LC3-II puncta (Additional file 2: 
(See figure on next page.)
Fig. 2 Expression of Nef does not affect ATG9A localization, ATG9A levels or autophagy. a HeLa cells, control (−) or transiently expressing HIV‑1 
Nef‑GFP (+), were fixed, permeabilized, immunostained with antibodies to endogenous ATG9A or TGN46, and imaged by confocal microscopy. 
Scale bar: 10 μm. Insets show enlarged views of the boxed areas. b, c Lysates of Jurkat or HeLa cells stably expressing GFP (−) or HIV‑1 Nef‑GFP 
(+) were subjected to SDS‑PAGE and immunoblotting with antibodies to ATG9A, LC3 or actin. The positions of molecular mass markers (in kDa) 
are indicated on the left. ATG9A and LC3 levels were quantified relative to actin levels. Bar graphs represent the mean ± SD from four independent 
experiments. Values were normalized to the ATG9A/actin ratio in the absence of Nef. Statistical significance was determined using an unpaired 
Student’s t‑test; ns: not significant (p > 0.05). d, e HeLa (d) or Jurkat (e) cells, stably expressing GFP (−Nef ) or Nef‑GFP (+Nef ), were treated for 
different times with 10 μM chloroquine (CQ). Cell lysates were analyzed by SDS‑PAGE and immunoblotting with antibodies to the indicated 
proteins. The positions of molecular mass markers (in kDa) are indicated on the left. Bar graphs represent the mean ± SD of the levels of LC3‑I 
and LC3‑II relative to the level of actin from three independent experiments. Values were normalized to the levels at time 0 in the absence of Nef. 
Statistical significance was analyzed using a one‑way ANOVA followed by a Holm‑Šídák post hoc test; ns: not significant (p > 0.05)
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Figure S5B, D), they had no effect on the overall distribu-
tion of GFP-Nef (Additional file 2: Figure S5A, C). From 
these experiments we concluded that the intracellular 
distribution of Nef-GFP is independent of ATG9A and of 
autophagy induction.
ATG9A promotes HIV‑1 infectivity
Because Nef and ATG9A did not affect each other’s levels 
or intracellular distribution, and Nef did not detectably 
alter autophagy, we focused our subsequent studies on 
the possibility that ATG9A could mediate the effects of 
Nef on the HIV-1 replication cycle independently of its 
role in autophagy. To address this question, we examined 
the release and infectivity of WT and Nef-deleted (ΔNef) 
HIV-1 particles produced in WT and ATG9A-KO HeLa 
and Jurkat cells (Fig.  3a). The procedure consisted of 
infecting HeLa or Jurkat cells with reverse-transcriptase 
(RT)-normalized amounts of WT or ΔNef HIV-1 par-
ticles pseudotyped with vesicular stomatitis virus G 
glycoprotein (VSV-G). After 8  h of infection, cells were 
washed and cultured in fresh medium. Two days later, 
the culture supernatant was filtered, and a portion was 
centrifuged to collect viruses. Viral and cell lysates were 
immunoblotted with antibodies to viral proteins to quan-
tify the efficiency of virus release (Fig. 3b, c). We noticed 
that the production of HIV-1 proteins was reduced in 
ATG9A-KO relative to parental HeLa cells for both WT 
and Nef-defective virus (Fig. 3b); this was not the case in 
Jurkat cells (Fig.  3c). While we do not know the reason 
for this difference, the key observation in these experi-
ments was that the ratio of released and cell-associated 
capsid protein CAp24 was unchanged by either ATG9A 
KO or Nef deletion (Fig. 3d, e). Therefore, we concluded 
that these mutations do not affect the efficiency of virus 
release. We subsequently used equal numbers of virus 
particles, normalized by reverse transcriptase (RT) activ-
ity, to infect CD4-positive TZM-bl cells, which express 
the luciferase (LUC) reporter gene under control of the 
HIV-1 long terminal repeat (LTR). Measurement of LUC 
activity in these cells allowed calculation of viral infectiv-
ity. Using this procedure, we observed that deletion of 
Nef decreased the infectivity of the virus released from 
WT HeLa and Jurkat cells to ~ 20% and ~ 10%, respec-
tively, of the WT virus control (Fig. 3f, g), as previously 
reported [56–60]. The greater effect of Nef deletion on 
HIV-1 infectivity in Jurkat cells relative to HeLa cells was 
in line with previous findings, and was likely due to the 
higher levels of SERINC3/5 expression in Jurkat cells [14]. 
Importantly, KO of ATG9A also reduced infectivity of the 
WT virus to ~ 30% and ~ 14% of the control in HeLa and 
Jurkat cells respectively (Fig. 3f, g). Combining Nef dele-
tion with ATG9A KO resulted in a further reduction of 
infectivity to ~ 12% and ~ 1% of the control from HeLa 
and Jurkat cells and WT virus, respectively (Fig.  3f, g). 
The difference between the infectivity of WT and ΔNef 
virus in ATG9A-KO cells was statistically significant 
(p < 0.05), indicating that the effects of Nef deletion and 
ATG9A KO are additive, and that ATG9A contributes to 
the infectivity of both WT and Nef-deleted HIV-1.
Nef‑ATG9A interaction is not required for HIV‑1 infectivity
We next addressed the question of whether the physical 
interaction of HIV-1 Nef with ATG9A is important for 
HIV-1 infectivity. To this end, we first sought to iden-
tify mutations in Nef that prevented its interaction with 
ATG9A. Among the mutations tested were glycine-2 to 
alanine (G2A) [61–64], methionine-20 to alanine (M2A) 
[65], tryptophan-58 and leucine-59 (WL) to two alanines 
(AA) [66], glutamate-65, -66, -67 and -68 (EEEE) to four 
alanines (AAAA) [67, 68] and proline-72 and -75 (PxxP) 
to two alanines (AxxA) [21] (Fig. 4a). The G2A mutation 
prevents myristoylation of Nef, abrogating its associa-
tion with membranes and most of its biological functions 
[61–64]. The other mutations were previously reported 
to prevent association of Nef with various cellular pro-
teins [65–69]. Pulldown assays such as those shown in 
Fig.  1e demonstrated that, while all mutations partially 
reduced interaction of transiently transfected Nef-FTS 
Fig. 3 ATG9A is required for HIV‑1 infectivity. a Flowchart representing the steps to measure HIV‑1 release and infectivity. Briefly, RT‑normalized 
HIV‑1 NL4‑3 particles, produced from WT or ATG9A‑KO HeLa or Jurkat cells, were used to infect TZM‑bl cells. These cells express the LUC (luciferase) 
reporter gene under control of the HIV‑1 long terminal repeat (LTR). Reporter gene expression is proportional to the number of infectious particles 
present in the initial inoculum. b, c WT and ATG9A‑KO HeLa (b) and Jurkat (c) cells were infected with WT or Nef‑defective (ΔNef ) pNL4‑3 for 8 h 
and the medium was replaced. Two days post‑infection, the culture supernatant was filtered, and viruses were collected by ultracentrifugation. Cell 
and virus lysates were analyzed by SDS‑PAGE and immunoblotting with anti‑HIV immunoglobulin (HIV‑Ig) to detect viral proteins  (Pr55Gag, CAp24), 
and with antibodies to HIV‑1 Nef, ATG9A and tubulin. The positions of molecular mass markers (in kDa) are indicated on the left. d, e Virus release 
was quantified by determining the amount of virion‑associated CAp24 relative to the level of total CAp24 in cells and viruses. Bar graphs represent 
the mean ± SD from four (d) or five (e) independent experiments. Values were normalized to the release of WT HIV‑1 from WT cells. Statistical 
significance was calculated using a one‑way ANOVA test; ns: not significant (p > 0.05). f, g RT‑normalized HIV‑1 virus stocks were used to infect 
TZM‑bl cells. Infection of reporter cells was measured by detection of LUC activity at 2 days post‑infection. Values were normalized to the infectivity 
of WT HIV‑1 from parental cells. Data were evaluated for statistical significance by using a one‑way ANOVA test (ns: p > 0.05, *p < 0.05, ****p < 0.0001)
(See figure on next page.)
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with endogenous ATG9A in HeLa cells, only the G2A 
mutation completely abrogated the interaction (Fig.  4b 
and Additional file 2: Figure S6). This finding is consistent 
with the Nef-ATG9A interaction occurring in association 
with membranes. We also tested the effects of combining 
two of the above mutations and found that the WL-EEEE 
(i.e., Mut1) and EEEE-PxxP (i.e., Mut2) mutations further 
reduced the Nef-ATG9A pulldown to ~ 10% that of WT 
Nef (Fig.  4b). These findings indicated that the region 
between Nef residues 58 and 75 is particularly important 
for interaction with ATG9A.
To test whether inhibition of Nef-ATG9A binding pre-
vented the enhancement of HIV-1 infectivity by Nef, we 
performed HIV-1 release and infectivity assays such as 
those shown in Fig. 3 using Nef mutants. We found that 
WT, ΔNef, Mut1 and Mut2 viruses were released with 
similar efficiency from Jurkat cells (Fig.  4c, d). Interest-
ingly, Mut1 exhibited decreased infectivity to the same 
extent as ΔNef (Fig.  4e), indicating that the WL and 
EEEE motifs are important for this function of Nef, as 
they are for CD4 [66] and MHC-I downregulation [68], 
respectively. However, Mut2 was as infectious as the WT 
virus (Fig. 4e), breaking the correlation between the Nef-
ATG9A interaction and infectivity. From these results, 
we concluded that ATG9A is required for optimal infec-
tivity of HIV-1 independently of its interaction with Nef.
ATG9A is dispensable for SERINC5 downregulation by Nef
We hypothesized that the Nef-independent function 
of ATG9A might involve downregulation of a host-cell 
restriction factor that impairs HIV-1 infectivity. In this 
regard, Nef was shown to increase HIV-1 infectivity by 
antagonizing the restriction factors SERINC3 and SER-
INC5 in the host cells [14–18, 65]. This antagonism was 
shown to involve downregulation of SERINC3/5 from 
the cell surface, preventing its incorporation into bud-
ding virions and thus its inhibitory effect on fusion of 
virions with target cells [14–18]. To test our hypothesis, 
we examined the Nef-induced downregulation of SER-
INC5-GFP in WT and ATG9A-KO Jurkat cells. Confocal 
microscopy analyses showed that in WT cells HIV-1 Nef-
mCherry induced redistribution of SERINC5-GFP from 
the plasma membrane to an intracellular compartment 
where the two proteins co-localized (Fig.  5a, b). KO of 
ATG9A had no effect on this redistribution, as well as on 
the expression level of SERINC5 (Fig. 5a, b). These exper-
iments demonstrated that SERINC5 downregulation 
by Nef is independent of ATG9A. Further experiments 
showed that overexpression of SERINC5 had no effect on 
virus release (Fig. 5c), but reduced the infectivity of WT 
and ΔNef viruses in WT cells (Fig.  5d). SERINC5 over-
expression also reduced the infectivity of WT and ΔNef 
viruses in ATG9A-KO cells, although the differences 
were not statistically significant (Fig. 5d).
The requirement of ATG9A for HIV‑1 infectivity 
is dependent on the Env glycoprotein
HIV-1 infection is dependent on the binding of Env 
to CD4 and coreceptors on target cells. HIV-1 Env is 
synthesized as a gp160 precursor that is proteolytically 
processed to generate the surface gp120 and transmem-
brane gp41 subunits [70]. Incorporation of Env into 
virions is essential for HIV-1 infectivity [71]. Because 
ATG9A KO impairs HIV-1 infectivity, we evaluated 
whether ATG9A is required for Env incorporation 
into virions by performing immunoblotting for gp41 
in virus particles released from WT and ATG9A-KO 
HeLa cells. We observed that, despite the requirement 
of ATG9A for optimal infectivity, ATG9A KO did not 
alter the levels of gp41 relative to CAp24 present in 
the released virions (Fig.  6a). To investigate whether 
the requirement of ATG9A for infectivity was never-
theless dependent on Env, we examined the infectivity 
of HIV-1 pseudotyped with the VSV-G glycoprotein 
(See figure on next page.)
Fig. 4 ATG9A‑Nef interaction is not required for HIV‑1 infectivity. a Schematic representation of HIV‑1 NL4‑3 Nef as described in Fig. 1a. Red 
arrowheads indicate residues that were mutated to alanine. Mut1 represents mutation of WL‑EEEE to AA‑AAAA and Mut2 mutation of EEEE‑PxxP 
to AAAA‑AxxA. b HeLa cells were transfected with plasmids encoding WT HIV‑1 Nef‑FTS, Nef‑FTS mutants (G2A, Mut1, or Mut2) or Myrlysin‑FTS, 
and cell extracts were incubated with Strep‑Tactin beads. The isolated proteins were subjected to SDS‑PAGE and immunoblotting with antibodies 
to FLAG and ATG9A. The positions of molecular mass markers (in kDa) are indicated on the left. The amount of ATG9A in the isolated samples was 
quantified relative to the amount of ATG9A in the input. Values were normalized to the ATG9A PD/input ratio in the WT condition. Bar graphs 
represent the mean ± SD from three independent experiments. Statistical significance was analyzed using a one‑way ANOVA test (****p < 0.0001). 
c RT normalized WT and Nef‑mutant NL4‑3 viruses produced in HEK‑293T cells were used to infect Jurkat cells for 8 h, and the medium was 
replaced. At 48 h post‑infection, cell and virus fractions were harvested and analyzed by immunoblotting with anti‑HIV immunoglobulin (HIV‑Ig), 
and antibodies to Nef and tubulin. In b and c, the positions of molecular mass markers (in kDa) are indicated on the left. d Virus release was 
quantified by determining the amount of virion‑associated CAp24 relative to the total amount of CAp24 in cells and virions. Bar graphs represent 
the mean ± SD from four independent experiments. Statistical significance was analyzed using a one‑way ANOVA test; ns: not significant (p > 0.05). 
e RT‑normalized HIV‑1 particles were used to infect TZM‑bl cells. Infection was determined by detection of LUC activity 2 days post‑infection. Data 
were evaluated for statistical significance using a one‑way ANOVA; ns: not significant (p > 0.05), *p < 0.01
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produced in WT and ATG9A-KO cells. These experi-
ments showed equal levels of VSV-G and CAp24 in 
viruses released by WT and ATG9A-KO cells (Fig. 6b), 
demonstrating that ATG9A does not affect incorpora-
tion of VSV-G glycoprotein into the virus. Importantly, 
the VSV-G-pseudotyped viruses produced in WT and 
ATG9A-KO cells were equally infections in the indi-
cator TZM-bl cells (Fig.  6b). Thus, replacement of 
HIV-1 Env with VSV-G overcame the requirement of 
ATG9A for optimal infectivity. This finding indicates 
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Discussion
The main conclusion of our study is that the host cell 
protein ATG9A is required for HIV-1 infectivity in an 
Env-dependent manner. We arrived at this conclusion 
by a rather circuitous route that started with TAP-MS 
experiments aimed at identifying cellular interactors 
for the Nef proteins of HIV-1 and SIV. This approach 
resulted in the identification of dozens of interactors, 
some known and some novel. Among the novel inter-
actors was ATG9A, which had not been previously 
implicated in HIV-1 replication or pathogenesis. The 
interaction of HIV-1 Nef with ATG9A was specific in 
that ATG9A was never identified in 411 other TAP-MS 
experiments recorded in the CRAPome database, and 
control proteins such as myrlysin and lyspersin did not 
significantly pull down ATG9A (Figs.  1e, 4b). Further-
more, G2A, WL-EEEE and EEEE-PxxP mutations in 
Nef abrogated the pulldown of ATG9A (Fig. 4b). These 
findings prompted us to analyze the biological signifi-
cance of the Nef-ATG9A interaction.
Because ATG9A is an essential component of the 
core autophagy machinery, we investigated whether 
Nef could alter autophagy via interaction with ATG9A. 
Previous studies have reported multiple connec-
tions between HIV-1 infection and autophagy [22, 
72–75]. In particular, Nef has been shown to perturb 
autophagy in both infected and bystander cell types, 
including macrophages, cardiomyocytes, astrocytes, 
mesenchymal cells and HeLa cells [22, 24, 76–81]. In 
our experiments, using HeLa cells and Jurkat T cells, 
however, Nef did not alter the intracellular localiza-
tion or levels of ATG9A (Fig. 2a, b). Moreover, Nef had 
no effect on the number of LC3 puncta and the levels 
of LC3-I and LC3-II in control or chloroquine-treated 
cells (Fig. 2c–e), indicating that neither autophagy ini-
tiation nor autophagic flux were affected by HIV-1 Nef. 
It is noteworthy that only one of the previous studies 
used HeLa cells, reporting a doubling of the number of 
LC3 puncta per cell upon Nef expression [76]. We do 
not know the reason for the difference with our results, 
although we should point out that our analyses were 
more extensive, including biochemical measurement of 
the levels of LC3 species. None of the previous studies 
used Jurkat T cells, which are a particularly relevant cell 
type for HIV-1 infection. From these observations, we 
concluded that, in the cells and conditions used in our 
studies, Nef had no discernible effect on ATG9A and 
autophagy.
Because Nef promotes HIV-1 infectivity through 
downregulation of restriction factors such as SER-
INC3/5 [14–18], we next examined the possibility 
that ATG9A could play a role in infectivity. Indeed, we 
found that ablation of the ATG9A gene in host cells 
reduced infectivity to a similar extent as deletion of 
the Nef gene in the virus (Fig.  3). However, additional 
observations indicated that these effects of Nef and 
ATG9A were independent. First, the decreases in HIV-1 
infectivity caused by Nef deletion and ATG9A KO were 
additive (Fig.  3d). In other words, deletion of Nef fur-
ther attenuated the already reduced infectivity of HIV-1 
produced in ATG9A-KO cells. Moreover, mutation of 
EEEE-PxxP residues in Nef abrogated interaction with 
ATG9A but did not alter infectivity (Fig. 4). Hence, the 
interaction of Nef with ATG9A identified in our initial 
experiments is not required for Nef to enhance HIV-1 
infectivity. In line with this conclusion, ATG9A KO did 
not prevent Nef from downregulating SERINC5 from 
the cell surface (Fig.  5), a well-established function of 
Nef in enhancement of HIV-1 infectivity.
Our experiments nonetheless led to the discovery 
that, independently of its interaction with Nef, ATG9A 
itself promotes infectivity. We speculate that ATG9A 
could do so by participating in the removal of a factor 
that inhibits infectivity, as previously demonstrated 
for the Nef-induced downregulation of SERINC3/5 
from the surface of the host cells [14–18]. This fac-
tor, however, is unlikely to be SERINC5 because the 
absence of ATG9A did not change the intracellular dis-
tribution of SERINC5-GFP or prevent the Nef-induced 
redistribution of plasma membrane SERINC5-GFP 
Fig. 5 ATG9A is dispensable for SERINC5 downregulation by Nef. a WT and ATG9A‑KO Jurkat cells transiently expressing SERINC5‑GFP minus (−) 
or plus (+) Nef‑mCherry were fixed, permeabilized, and imaged by confocal microscopy. Scale bars: 10 μm. b Lysates of WT or ATG9A‑KO Jurkat 
cells, transiently expressing mCherry (−) or HIV‑1 Nef‑mCherry (+) in addition to SERINC5‑GFP, were subjected to SDS‑PAGE and immunoblotting 
with antibodies to ATG9A, mCherry, GFP or actin. The positions of molecular mass markers (in kDa) are indicated on the left. The different bands 
detected by the GFP antibody correspond to different glycosylation forms of SERINC5 [17]. c WT and ATG9A‑KO HeLa cells were co‑transfected with 
50 ng of SERINC5 and 1 μg of WT or ΔNef pNL4‑3 for 6–8 h and the medium was replaced. One day later, the culture supernatant was filtered, and 
virus pellets were collected by ultracentrifugation. Cell and virus lysates were analyzed by SDS‑PAGE and immunoblotting with HIV‑Ig to detect 
viral proteins  (Pr55Gag, CAp24), and with antibodies to HIV‑1 Nef, ATG9A and tubulin. In b and c, the positions of molecular mass markers (in kDa) 
are indicated on the left. d Infectivity of virions was measured in TZM‑bl cells as in Fig. 3. Values were normalized to the infectivity of WT HIV‑1 from 
parental HeLa cells in the absence of SERINC5. Data were evaluated for statistical significance by using a one‑way ANOVA followed by a Holm‑Šídák 
post hoc test; ns: not significant (p > 0.05), *p < 0.05, ****p < 0.0001)
(See figure on next page.)
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to intracellular compartments (Fig.  5). Because the 
requirement of ATG9A is independent of Nef, we can-
not rule out the alternative possibility that ATG9A 
promotes the incorporation of a positive factor into 
the budding virions. In any event, these hypothetical 
regulators would act through Env, as the requirement 
of ATG9A for particle infectivity can be overridden 
by substitution of HIV-1 Env with VSV-G (Fig.  6b). 
Because ATG9A is thought to be a lipid transporter 
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Fig. 6 Env‑dependence of ATG9A role in HIV‑1 infectivity. a WT HIV‑1 particles, produced from WT and ATG9A‑KO HeLa cells, and cell lysates were 
analyzed by SDS‑PAGE and immunoblotting with HIV‑Ig to detect CAp24, and with antibodies to gp41 and ATG9A. The positions of molecular mass 
markers (in kDa) are indicated on the left. The incorporation of gp41 was quantified by determining the amount of virion‑associated gp41 relative 
to CAp24. RT‑normalized HIV‑1 virus stocks were used to infect TZM‑bl cells. Infection of reporter cells was measured by detection of LUC activity 
2 days post‑infection. Values were normalized to parental HeLa cells. Statistical significance from three independent experiments was determined 
using an unpaired Student’s t‑test; ns: not significant (p > 0.05), ****p < 0.0001). b VSV‑G pseudotyped HIV‑1 particles were produced from WT and 
ATG9A‑KO HeLa cells, and cell lysates were analyzed by SDS‑PAGE and immunoblotting with HIV‑Ig to detect CAp24, and with antibodies to VSV‑G 
and ATG9A. The positions of molecular mass markers (in kDa) are indicated on the left. The incorporation of VSV‑G was quantified by determining 
the amount of virion‑associated VSV‑G relative to CAp24. RT‑normalized HIV‑1 particles were used to infect TZM‑bl cells. Virus infectivity was 
determined as in panel B. c Model for the role of ATG9A in HIV‑1 infectivity. ATG9A promotes HIV‑1 infectivity independently of Nef. ATG9A could 
promote the removal of an inhibitor or the incorporation of an activator of the infectivity of the viral particles. This effect of ATG9A on HIV‑1 
infectivity is dependent on HIV‑1 Env, as pseudotyping with VSV‑G overcomes the infectivity defect
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environment in the viral envelope that promotes Env- 
but not VSV-G-mediated fusion with the host cell 
membrane. Testing this hypothesis will require the 
determination of the protein and lipid composition of 
HIV-1 particles produced in the presence or absence of 
ATG9A.
Conclusions
In summary, the present study (1) identified novel inter-
actors of several Nefs, including ATG9A, and (2) demon-
strated a requirement of ATG9A in the HIV-1-producing 
cells for optimal infectivity of the viral progeny. Although 
one set of findings led to the other, the interaction of 
ATG9A with Nef and its role in the promotion of viral 
infectivity turned out to be unrelated phenomena, i.e., 
Nef and ATG9A independently contribute to enhanced 
HIV-1 infectivity. Nevertheless, these findings should 
enable further studies of Nef and ATG9A function in 
HIV-1 propagation. The novel Nef interactors identified 
here could mediate some of the known effects of Nef on 
HIV-1 replication, infectivity and pathogenesis. The other 
two hits that were further validated in pulldown assays, 
PAK3 and SPTLC2, are particularly good candidates for 
mediating Nef actions. The requirement of ATG9A addi-
tionally points to a role of this protein in the production 
of infectious HIV-1 particles, possibly by a mechanism 
that is distinct from its role in autophagy.
Materials and methods
Plasmids and mutagenesis
The Nef proteins from the HIV-1 NL4-3 strain and 
from three SIV strains (cpz GAB1, mac239 and smm 
FWR1), tagged with a C-terminal FTS tag, were cloned 
into a pcDNA5/FRT/TO Dox-inducible plasmid. The 
human ATG9A, myrlysin (also known as LOH12CR1 
and BORCS5), and lyspersin (also known as C17orf59 
and BORCS6), and the HIV-1 pNL4-3 Nef cDNAs were 
cloned into a pcDNA3.1 plasmid encoding a single C-ter-
minal FTS tag. The cDNAs encoding human ATG9A 
and SERINC5, and Nef from pNL4-3, were cloned into 
pEGFP-N1 (Clontech). Nef from pNL4-3, was cloned 
into pmCherry-N1 (Clontech). The full-length infectious 
HIV-1 molecular clone pNL4-3 [82], and its Nef-defec-
tive (pNL4-3 ΔNef) [83] and Env-defective (pNL4-3/
KFS) [84] derivatives have been described previously. 
The plasmid pHCMV-G [85], encoding the G glycopro-
tein of vesicular stomatitis virus (VSV) was kindly pro-
vided by Dr. Jane Burns (University of California, San 
Diego, La Jolla, CA). All mutations were generated by 
site directed mutagenesis (QuikChange, Agilent, or  Q5® 
Hot Start High-Fidelity 2X, NEB) and confirmed by DNA 
sequencing.
Cell culture, transfection and infection
HEK-293T cells, and WT and ATG9A-KO HeLa cells, 
were cultured in Dulbecco-modified Eagle’s medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 
2  mM l-glutamine at 37  °C, 5%  CO2. Transient plas-
mid transfection of HeLa cells was performed using 
Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions. Immunoblot analysis, co-immu-
noprecipitations and immunofluorescence microscopy 
experiments were done 24 h after transfection. WT and 
ATG9A-KO Jurkat E6.01 cells were grown in Roswell 
Park Memorial Institute 1640 (RPMI-1640) medium con-
taining 10% FBS and 2 mM l-glutamine at 37 °C, 5%  CO2. 
Jurkat cells were infected for 72  h with lentiviral parti-
cles. Briefly, 1 million cells were centrifuged for 30 min at 
1500 rpm with supernatant containing viruses in 500 μl 
complete medium supplemented with 2.5 μg polybrene. 
After 4  h of incubation at 37  °C, medium was replaced 
with complete DMEM medium.
Tandem affinity purification and mass spectrometry 
(TAP‑MS)
HEK-293T cells were stably transfected with plasmids 
encoding the FTS-tagged HIV-1 and SIV Nef constructs 
and the empty FTS vector described above. Cells were 
lysed in 50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 5 mM 
EDTA, and 0.5% NP-40 supplemented with proteinase 
inhibitor cocktail (Roche) for 30  min. Cell lysates were 
cleared by centrifugation at 17,000×g for 15  min and 
incubated overnight with Strep-Tactin resin (IBA) at 
4  °C. Bound proteins were washed 3 times with 50 mM 
Tris-HCl (pH 7.4), 300 mM NaCl, 5 mM EDTA, and 0.5% 
NP-40 and eluted with 2.5  mM desthiobiotin. Proteins 
were further purified using FLAG M2 antibody-coated 
beads (Sigma). After incubation for 3 h at 4  °C, samples 
were washed 3 times as previously described and eluted 
twice with 500 μl of 500 μg/ml 3 × FLAG peptide (Sigma). 
Proteins were precipitated with 10% trichloroacetic acid 
(TCA) for 15  min at − 20  °C, centrifuged for 30  min at 
4  °C, washed twice with acetone and air-dried. Samples 
were analyzed by liquid chromatography (LC)/MS at the 
Taplin MS facility (Harvard Medical School).
Filtering and analysis of mass spectrometry data
Initial datasets were filtered against the experimen-
tal control of the vector alone, and proteins with two 
or more unique peptides (i.e., number of peptides that 
can be assigned as being unique to that protein) were 
selected for analysis. To remove additional contaminants 
not present in the negative control, the datasets under-
went a second filtering using the Contaminant Reposi-
tory for Affinity Purification Mass Spectrometry Data 
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(CRAPome, www.crapo me.org). Two values from the 
CRAPome database were used from the database to fil-
ter the dataset: the “average spectral count” (AveSC), 
which is the average number of peptides in the CRA-
Pome control experiments where the protein appeared, 
and the “experiment appeared” (ExpAP) ratio, which is 
the number of times that protein appeared in a CRA-
Pome control experiment divided by the total number of 
CRAPome experiments analyzed. By multiplying AveSC 
and ExpAP, we obtained an estimate of both the number 
of times the protein was identified in a CRAPome nega-
tive control and its abundance when it was identified in 
one of the CRAPome control experiments. If this value 
was lower than the threshold (set at 0.025), the proteins 
were assigned as specific hits in our analysis, as we con-
sidered them as not frequently or abundantly appearing 
in the CRAPome database of negative control experi-
ments. The BioGRID database was used to map pro-
tein–protein interactions. Positive interactions were 
mapped as connected nodes. The CRAPome filtering and 
BioGRID analyses were performed using the respective 
APIs in Python 3.7.2 with the networks generated using 
NetworkX and formatted for publication using Adobe 
Illustrator. RPL17 was manually removed from the data-
set as it was annotated as RPL17-C18orf32 in the original 
dataset and RPL17 in the CRAPome, leading to it being 
incorrectly included despite having a CRAPome score 
above the threshold.
DSP cross‑linking
Prior to Strep-Tactin pulldown, HeLa cells were cross-
linked to stabilize protein–protein interactions. One 
10-cm culture dish of cells per sample was transfected 
with Lipofectamine 2000 for 24  h. Cells at 90% conflu-
ency were washed twice with ice-cold PBS containing 
0.1 mM  CaCl2 and 1.0 mM  MgCl2 (PBSCM) buffer. DSP 
(ThermoFisher) was dissolved in DMSO before dilution 
into PBSCM buffer and addition to the cell suspension 
at 1  mM final concentration. Cross-linking was per-
formed at 4  °C for 6  h. The DSP reaction was stopped 
by removing the DSP solution and adding 1 × ice-cold 
DSP quenching solution (20 mM Tris pH 7.4 in PBSCM 
buffer) at 4 °C for 15 min. Cells were washed twice with 
ice-cold PBSCM buffer prior to lysis.
Strep‑Tactin precipitation
Cells were lysed in 50  mM Tris-HCl (pH 7.4), 300  mM 
NaCl, 5 mM EDTA, and 0.5% NP-40 supplemented with 
proteinase inhibitor cocktail (Roche) for 30  min. Cell 
lysates were cleared by centrifugation at 17,000×g for 
15 min and incubated overnight with Strep-Tactin resin 
(IBA) at 4  °C. Bound proteins were washed three times 
with 50  mM Tris-HCl (pH 7.4), 300  mM NaCl, 5  mM 
EDTA and 0.5% NP-40. Beads were resuspended with 
2× NuPage LDS sample buffer (ThermoFischer) sup-
plemented with 50 mM DTT and incubated at 37 °C for 
15 min. Beads were pelleted by centrifugation and eluates 
subsequently analyzed by SDS-PAGE.
Antibodies
We used the antibodies in parentheses to the follow-
ing antigens: ATG9A (Abcam, catalog #108338), FLAG 
M2 (Sigma, F1804), PAK3 (Abnova, PAB2300), SPTLC2 
(Abcam, ab23696), GFP-HRP (MACS, 130091833), 
actin-HRP (Sigma, A3854), beclin 1 (Cell Signaling, 
3738), ATG7 (Cell Signaling, 8558), ATG5 (Cell Signal-
ing, 12994), ATG12 (Cell Signaling, 4180), ATG16 (Cell 
Signaling, 8089), LC3 (Cell Signaling, 3868), LAMP-1 
(Cell Signaling, 9091), SNAP29 (Abcam, 138500), gp41 
(NIH AIDS Reagent Program, 2F5), TGN46 (Bio-Rad, 
AHP500G), anti-HIV immunoglobulin (NIH AIDS Rea-
gent Program, HIV-Ig), Nef (NIH AIDS Reagent Pro-
gram, 2949), α-tubulin (Sigma, T5168), VSV-G (Sigma, 
V5507), Alexa Fluor 488-conjugated donkey anti-rabbit 
IgG (Invitrogen, A21206), Alexa Fluor 488- conjugated 
donkey anti-mouse IgG (Invitrogen, A21202), Alexa 
Fluor 555-conjugated donkey antirabbit IgG (Invitrogen, 
A31572), Alexa Fluor 555-conjugated donkey anti-mouse 
IgG (Invitrogen, A31570), Alexa Fluor 555-conjugated 
donkey anti-sheep IgG (Invitrogen, A21436), HRP-conju-
gated donkey anti-rabbit IgG (GE Healthcare, NA934V), 
and HRP-conjugated sheep anti-mouse IgG (GE Health-
care, NXA931).
SDS‑PAGE and immunoblotting
Samples were incubated at 37  °C in sample buffer for 
5 min (ATG9A detection) or 95 °C for 2 min and loaded 
onto a 10% polyacrylamide gel using 1× Tris-glycine-
SDS (IPM scientific) running buffer and transferred onto 
a nitrocellulose membrane (Bio-Rad). Membranes were 
saturated with 3% milk (Bio-Rad) for 2  h at 4  °C and 
incubated overnight at 4  °C with the indicated primary 
antibodies. HRP-conjugated secondary antibodies were 
incubated with the membrane at room temperature for 
1 h. HRP signal was detected using the Clarity or Femto 
ECL kit (ThermoFisher). Images were captured with the 
Chemidoc system (Bio-Rad). Protein bands were quanti-
fied using Imagelab-Chemidoc software (Bio-Rad).
Immunofluorescence microscopy
Cells were cultured on coverslips in a 24-well plate, and 
24 h after transfection fixed with 4% paraformaldehyde in 
PBSCM for 15 min at room temperature (RT). Cells were 
permeabilized with 0.2% Triton X-100 in PBSCM for 
10 min at room temperature, except for LC3 staining in 
which cells were treated for 10 min with 100% methanol 
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previously stored at − 20  °C. Primary antibodies and 
Alexa-conjugated secondary antibodies were diluted in 
0.2% BSA-containing PBSCM to probe proteins of inter-
est. Coverslips were mounted on glass slides with DAPI-
Fluoromount-G (EMS). Confocal microscopy images 
were collected using a Zeiss LSM 710 confocal micro-
scope with a Plan Apochromat 63 × objective. Image 
analysis was performed with Fiji software.
Chloroquine treatment
To measure autophagic flux, HeLa and Jurkat cells were 
treated for different times with 10 μM chloroquine (CQ). 
A control condition without treatment was performed in 
parallel. Following incubation, cells were lysed for 15 min 
in 1 ml of ice-cold lysis buffer containing 300 mM NaCl, 
50 mM Tris pH 7.4, 1 mM EDTA, 1% Triton X-100 and 
EDTA-free complete protease inhibitors (Roche). Cell 
lysates were collected, centrifuged at 17,000×g for 10 min 
at 4 °C and further analyzed by immunoblotting.
Induction of autophagy
Starvation was performed by incubating HeLa and Jur-
kat cells in Hanks’ balanced salt solution (HBSS) for 
1  h at 37  °C. Cells were briefly washed once with star-
vation medium before incubation. Torin1 treatment 
was performed by incubating cells for 2  h at 37  °C in 
DMEM or RPMI-1640 with 200  mM of the drug. Fol-
lowing treatment, cells were lysed and analyzed by 
immunofluorescence.
CRISPR/Cas9 knock‑out
The ATG9A gene was inactivated using the CRISPR/Cas9 
system. Briefly, two 20-base pair (bp) targeting sequences 
(TAT AGG AGG CCT CTA GGC GC and CTG TTG GTG 
CAC GTC GCC GA) were introduced separately into the 
px458 plasmid (Addgene). HeLa and Jurkat cells were co-
transfected with both plasmids. After 72 h, single clones 
were selected for expression of GFP by fluorescence-acti-
vated cell sorting (FACS) and seeded on a 96-well plate. 
After 12 days, single clones were analyzed by immunob-
lotting to confirm the absence of ATG9A.
Virus production
VSV-G-pseudotyped virus stocks were prepared 
in HEK-293T cells by transfection with the indi-
cated plasmids using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions. 
Briefly, Lenti-X HEK-293T cells were co-transfected 
with psPAX2 (Addgene), pADV (Promega), pMD2G 
(Addgene) and Nef-expressing construct in pLex F67 
mEmerald to generate VSV-G pseudotyped viruses. 
The supernatant containing viruses was collected 48 h 
after transfection, and viruses were concentrated using 
lentivirus precipitation solution (Alstem) according to 
the manufacturer’s protocol. For production of pNL4-3 
viruses, HEK-293T cells were co-transfected with WT, 
pNL4-3 or pNL4-3ΔNef in the presence of VSV-G 
expression vector pHCMV-G. After overnight trans-
fection, the medium was replaced with fresh DMEM. 
Viruses were collected 24  h later and subjected to 
reverse transcriptase (RT) activity assay, as previously 
described [86].
Virus assembly and release
HeLa (parental or ATG9A-KO) cells were transfected 
with the indicated plasmids or infected with RT-normal-
ized VSV-G-pseudotyped HIV-1 (NL4-3 or NL4-3ΔNef). 
Jurkat cells were infected with RT-normalized NL4-3 or 
NL4-3ΔNef particles pseudotyped with VSV-G. After 
8 h of infection, cells were washed and medium replaced. 
Virus-containing supernatants were filtered 48  h later, 
and virus particles were collected by ultracentrifugation. 
A portion of virus-containing supernatant was stored for 
infectivity and RT assays. Cell and viral pellets were lysed 
[87]. The virus release efficiency (VRE) was calculated as 
the amount of virion-associated CAp24 as a fraction of 
total (cell- and virion-associated) CAp24 quantified by 
immunoblot analysis.
Infectivity assay
For LUC-based, single-cycle infectivity assays, RT-
normalized virus stocks were used to infect the  CD4+/
CXCR4+/CCR5+ HeLa derivative TZM-bl (obtained 
from J. Kappes through the National Institutes of 
Health AIDS Research and Reference Reagent Pro-
gram, Bethesda, MD). This indicator cell line contains 
integrated copies of the β-galactosidase and LUC genes 
under the control of the HIV-1 LTR [88]. Infection effi-
ciency was determined by measuring LUC activity 48 h 
post-infection as previously described [89].
Statistical analysis
Analysis and plotting of data were performed using 
the GraphPad Prism 7.0 software (GraphPad Soft-
ware, La Jolla California USA) and are expressed as the 
mean ± SD. The statistical significance of multiple sam-
ples was assessed via a one-way ANOVA analysis of vari-
ance (ANOVA), in addition to a Holm-Šídák post hoc 
test in some case. The unpaired t test was applied when 
two groups were compared. The results were accepted as 
significantly different when p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 
or p ≤ 0.0001.
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Additional files
Additional file 1: Table S1. Identification of HIV‑1 and SIV Nef interactors 
by the TAP‑MS protocol outlined in Fig. 1b. Initial datasets were filtered 
against the experimental control of the empty vector. The “IPI” column 
provides the International Protein Index identification code referring to 
the name of the protein in the “User input” column. The “unique peptide” 
column indicates the number of distinct peptides used to identify the 
protein whereas the “total peptide” column indicates the total number 
of identified peptides matched for the protein. Raw data were filtered 
against the CRAPome database and several values were generated. The 
experiment appeared (ExpAP) ratio indicates the number of times that 
protein appeared in a control experiment divided by the total number of 
experiments analyzed. The column “ExpAP calculated” provides the value 
of the calculated ratio from the “ExpAP” column. The average spectral 
count (Ave SC) is the average number of peptides in the experiments 
where the protein appeared. Max SC is the highest number of peptides 
found in a single experiment. By multiplying AveSC and ExpAP, we 
obtained an estimate of both the number of times the protein was identi‑
fied in a negative control and its abundance when it was identified.
Additional file 2: Fig. S1. HIV and SIV Nef interactors. (A) BioGRID interac‑
tion map of SIV Nefs with host proteins identified by TAP‑MS. (B) BioGRID 
interaction map of proteins identified by TAP‑MS that interact with at least 
two Nef proteins. Fig. S2. Nef has no effect on the punctate appearance 
and staining intensity of endogenous LC3‑II. (A) WT HeLa cells, stably 
expressing HIV‑1 Nef‑GFP or GFP, were fixed, permeabilized, immu‑
nostained with antibody to LC3 and imaged by confocal microscopy. 
Scale bar: 10 μm. (B) The same analysis was performed on Jurkat cells. 
Fig. S3. Nef has little or no effect on levels of autophagy proteins. Lysates 
of WT Jurkat and HeLa cells, stably expressing GFP (−) or HIV‑1 Nef‑GFP 
(+), were analyzed by SDS‑PAGE and immunoblotting with antibodies to 
different autophagy proteins (beclin 1, ATG7, ATG5, ATG12, ATG16, LAMP‑1 
and SNAP29) and to actin. The positions of molecular mass markers (in 
kDa) are indicated on the left. The expression levels of the autophagy 
proteins were quantified relative to actin levels. Bar graphs represent the 
mean ± SD from four independent experiments. Statistical significance 
was evaluated using an unpaired Student’s t‑test (ns: p > 0.05, *p < 0.05, 
**p < 0.01, ***p < 0.001). Fig. S4. Expression of ATG9A does not affect the 
levels or localization of Nef. WT and ATG9A‑KO HeLa (A, B) or Jurkat (C, 
D) cells stably expressing Nef‑GFP were analyzed by immunoblotting (A, 
C) and immunofluorescence microscopy (B, D) using antibodies to the 
indicated antigens. In A and C, the positions of molecular mass markers 
(in kDa) are indicated on the left. Bar graphs represent the mean ± SD of 
the levels of Nef‑GFP relative to the levels of actin from three independent 
experiments. Statistical significance was determined using an unpaired 
Student’s t‑test (ns: p > 0.05). In B and D, cells were fixed, permeabilized, 
immunostained with antibody to ATG9A and observed by confocal 
microscopy. Scale bars: 10 μm. Fig. S5. Localization of Nef is not affected 
by induction of autophagy. (A, B) WT HeLa cells, stably expressing HIV‑1 
Nef‑GFP, were incubated in medium containing Torin1 for 2 h or HBSS 
medium for 1 h at 37 °C. Cells were then fixed, permeabilized, immu‑
nostained with antibody to ATG9A and LC3, and imaged by confocal 
microscopy. (A) Nef‑GFP and ATG9A were imaged by confocal microscopy. 
Scale bar: 10 μm. (B) The number of LC3‑II puncta per cell was counted 
for 20 cells per biological replicate for a total of three independent experi‑
ments using the ‘Analyze particles’ function of the Image J software. Bar 
graphs represent the mean ± SD of LC3‑II puncta. Statistical significance 
was determined using a one‑way ANOVA test (***p < 0.001, ****p < 0.0001). 
(C, D) The same analysis was performed on Jurkat cells. (**p < 0.01, 
***p < 0.001). Fig. S6. ATG9A‑Nef interaction requires residues in the 
58–75 region of Nef. HeLa cells were transiently transfected with plasmids 
encoding WT HIV‑1 Nef‑FTS, Nef‑FTS mutants (G2A, M20A, WL, EEEE or 
PxxP) (see Fig. 4a) or myrlysin‑FTS, and cell extracts were incubated with 
Strep‑Tactin beads. The isolated proteins were subjected to SDS‑PAGE 
and immunoblotting with antibodies to FLAG and ATG9A. The positions 
of molecular mass markers (in kDa) are indicated on the left. The amount 
of ATG9A in the isolated samples was quantified relative to the amount 
of ATG9A in the input. Values were normalized to the ATG9A PD/input 
ratio in the WT condition. Bar graphs represent the mean ± SD from four 
independent experiments. Statistical significance was analyzed using an 
unpaired Student’s t‑test (**p < 0.01, ***p < 0.001, ****p < 0.0001).
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